Minerva Neurosciences Inc. buy DomRuinart
Zusammenfassung
Diese Einschätzung wurde am 17.10.22 mit einem Endkurs von 5,67 € beendet. Stark abwärts ging es für die BUY Einschätzung von DomRuinart zu Minerva Neurosciences Inc. mit einer Rendite von -34,41 %. DomRuinart hat 50% Zuversicht bei dieser EinschätzungMinerva Neurosciences (Symbol NERV) (WKN A3DMH5) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative and cutting-edge therapies for central nervous system (CNS) disorders. With a primary focus on neuropsychiatric and neurodegenerative diseases, Minerva Neurosciences aims to address the unmet needs in the treatment of conditions such as schizophrenia, Parkinson's disease, and insomnia. Listed on the stock exchange and driven by a team of experts in neuroscience and biopharmaceutical development, the company strives to improve patients' quality of life and advance the field by translating robust scientific discoveries into groundbreaking therapies that can potentially transform the lives of millions suffering from these debilitating disorders.
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J |
|---|---|---|---|
| Minerva Neurosciences Inc. | 1,71 % | 1,71 % | -14,39 % |
| iShares Core DAX® | 2,59 % | -1,86 % | 13,24 % |
| iShares Nasdaq 100 | 3,55 % | -2,06 % | 38,29 % |
| iShares Nikkei 225® | 0,69 % | -8,70 % | 17,51 % |
| iShares S&P 500 | 2,21 % | -1,99 % | 27,63 % |